RxDoctor Payments Data

Karen Deal

Family · Statesboro, GANPI 1093856767

Payments from drug & device makers

$907in general payments, 2019–2025

Across 53 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199
  • Novo Nordisk$97
  • Boston Scientific$77
  • Pfizer$51
  • Dexcom, Inc.$50
  • Takeda Pharmaceuticals U.S.A., Inc.$45
  • plus $387 from 17 others

What the payments were for

  • Food & beverage$907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$907 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$170,770
Medicare patients
285
Services billed
2,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide17$17,748
BriviactBrivaracetam11$17,151
Lagevrio (Eua)Molnupiravir11$10,962
Atrovent HfaIpratropium Bromide13$6,413
Lacosamide21$4,623
Advair HfaFluticasone Propion/Salmeterol11$3,635
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen127$2,149
Memantine Hcl31$1,537
Oxycodone Hcl84$1,528
Gabapentin68$1,451
Tramadol Hcl97$1,383
Bethanechol Chloride13$1,258
Atorvastatin Calcium67$1,227
Lorazepam99$1,187
Potassium Chloride65$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$20$17,74817 claims
MerckLagevrio (Eua)$13$10,96211 claims
Sanofi-aventis U.S. LLCLantus$40$80611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →